Symbiotec Pharmalab Limited · NSE:SYMBIOTEC
Symbiotec Pharmalab — Q1 FY2027 Earnings Presentation
31 slides from Symbiotec Pharmalab's earnings presentation, Sep 21, 2026
Slide 1: Regulation 30 filing cover letter to stock exchanges
September 21, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai – 400001 Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub: Invest
Slide 2: Symbiotec Pharmalab Limited Q1FY27 Investor Presentation
Symbiotec Pharmalab Limited Q1FY27 Investor Presentation September 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Symbiotic Pharmalab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 4: IPO & Market Debut: A New Chapter. A Significant Milestone.
IPO & Market Debut : A New Chapter. A Significant Milestone. Details of IPO Listing of Symbiotec Pharmalab Limited in September 2026 Listing done on BSE & NSE IPO Price : Rs. 988 per share Issue Size: Rs. 1,757 Cr • Fresh Issue: Rs. 150 Cr • Offer for Sale: Rs. 1,607 Cr Objects of the Issu
Slide 5: Q1FY27 Performance Highlights
Q1FY27 Performance Highlights 4
Slide 6: Q1FY27 Key Business Updates
Q1FY27 Key Business Updates APIs Products Complex Injectables Biotech - CDMO Services Sales growth steady at 6% in Q1 Licensing agreement for Industrial Biotech : distribution of two DCV products o Growth further expected to in US o Customers on-boarded pick up in subsequent quarters o Term-sh
Slide 7: Q1 FY27 Financials Highlights
Q1 FY27 Financials Highlights Steady API growth offset by expenses from non-revenue generating New Bizs Consol Revenue (Rs. in Crs) Consol EBITDA (Rs. in Crs) Consol PAT (Rs. in Crs) • Drag of expenses from new 29% 21% 15% 6% businesses not yet generating +7% revenues 218.2 58.0 29.9 - Opex - Rs. 23
Slide 8: ₹1,000+ Crs capex invested in New Businesses
₹ 1,000+ Crs capex invested in New Businesses Revenue to commence in the next 6–12 months ₹ 1,475 Crs ₹ 1,666 Crs 39% 61% Total Gross Capex Share of Total Gross Capex Share of Gross Capex in Gross Capex (est end FY27) currently generating revenue New Projects yet to (as on 30th June 2026) Generate R
Slide 9: Management Commentary
Management Commentary Commenting on Q1FY27 performance, Mr. Anil Satwani, Chairman & Managing Director of Symbiotec Pharmalab Limited, said: "Our first results as a listed company reflect a business with a steady growing core and two new growth engines for the future. The API business — built over t
Slide 10: Q1FY27 Consolidated Profit & Loss Statement
Q1FY27 Consolidated Profit & Loss Statement Particular (Rs. in Crs) Q1 FY27 Q1 FY26 Y-o-Y Revenue from Operations 218.2 203.2 7% Gross Profit 142.6 125.8 13% Gross Margins (%) 65% 62% 300 bps Operating Expenses - API Business 74.2 65.7 Operating Expenses - New Businesses 23.2 2.2 Reported EBIDTA 45.
Slide 11: About Symbiotec Pharmalab
About Symbiotec Pharmalab 10
Slide 12: Symbiotec: R&D Driven Pharmaceutical and Biotech Company
Symbiotec: R&D Driven Pharmaceutical and Biotech Company Only Company globally having Market Global Leader Global Leader 57% presence across the top 10 Leadership in Corticosteroid and in Hydrocortisone, Testosterone, Average Market Share in corticosteroid & steroidal Steroidal Hormone APIs(1) and
Slide 13: Our Ethos Shaping Our Evolution
Our Ethos Shaping Our Evolution Drives incremental innovation 2 through complex product launches Proactive in embracing new 1 technologies (E.g.: One of the first generics players (E.g.: Biotransformation, globally to produce DCVs(1), Precision Fermentation, Technology One of the few companies globa
Slide 14: Symbiotec's Investment in Scale To Address Expanding Demand & Commitment to Compliance
Symbiotec’s Investment in Scale To Address Expanding Demand & Commitment to Compliance Phase 1: 2004 to 2010 Phase 2: 2011 to 2020 Phase 3: 2021 to date Building leadership in steroids and hormones Scaling fermentation capabilities Leveraging fermentation to expand horizons Cumulative maximum capaci
Slide 15: Vertically Integrated "Farm / Microbe to Pharmacy" Approach
Vertically Integrated “Farm / Microbe to Pharmacy” Approach Driving Cost Efficiency and Enabling Expansion Across Adjacencies Biotech - CDMO (Bio-Pharma & Make vs Buy Bio-manufacturing) Decision-Making Flexibility for KSMs of 80%+ product portfolio(3) Biotransformation / Organic Fermentation Chemist
Slide 16: What Differentiates Symbiotec?
What Differentiates Symbiotec? Global Leadership in Corticosteroid 1 and Steroidal-Hormone APIs Ability to Leverage Science and Existing Competencies to Increase TAM and 2 Deepen Intellectual Property-driven Offerings Fully-Invested, Multi-scale, Vertically 3 Integrated Manufacturing Platform with C
Slide 17: Delivering End-to-End Solutions to Global Partners
1 Delivering End-to-End Solutions to Global Partners A Supplying products to over 200 customers in over 40 countries B Retain & grow long-term relationships with broad customer base Domestic Regulated Markets 2 out of Top 5 42% Customers are innovators FY26 Exports 67% Revenues by vintage of relatio
Slide 18: Expanding Across Adjacencies: Complex Injectables (1/2)
Leveraging Core Platforms and Existing Strengths To Expand Across Adjacencies and 2.1 Deepen Intellectual Property-Driven Offerings Across Verticals (1/2) Complex Injectables Innovators Dominated Market Commercialization One of the first generics globally to develop DCV through backward integration
Slide 19: Expanding Across Adjacencies: Biotech - CDMO Services (2/2)
Leveraging Core Platforms and Existing Strengths To Expand Across Adjacencies and 2.2 2.1 Deepen Intellectual Property-Driven Offerings Across Verticals (2/2) Biotech - CDMO Services The India Advantage Commercialization One of India’s largest industrial-scale fermentation capacities Bio-Pharma CDMO
Slide 20: Fully-Invested, Multi-scale, Vertically Integrated Manufacturing Platform
3 Fully-Invested, Multi-scale, Vertically Integrated Manufacturing Platform Operating leverage and future earnings potential from investments in infrastructure Scaled manufacturing infrastructure Chemical Synthesis (MT) Fermentation (KL) DCV (mn) Capacity 584.67 584.67 584.67700.00 20.00 92MT Rau, I
Slide 21: Science Based Platform with Continuous Investment in R&D
4 Science Based Platform with Continuous Investment in R&D Focused innovation: R&D efforts across three interlinked platforms Continuous investment in R&D… R&D spend as % of sales Capabilities: Capabilities: Hydrogenation Biotransformation Aromatisation Biosynthesis Cryogenic / Grignard
Slide 22: Seasoned Leadership Supported by Experienced Management and Marquee Investors
5 Seasoned Leadership Supported by Experienced Management and Marquee Investors Anil Satwani Sushil Satwani Kashish Satwani Promoter, Chairman and Managing Director, Promoter, Director – Commercial Promoter, President – HR Over 30 years of experience in the 23+ years of experience 23+ years of exper
Slide 23: Multiple Building Blocks in Place to Fuel Growth Strategies (1/2)
6.1 Multiple Building Blocks in Place to Fuel Growth Strategies (1/2) 1 2 3 Expand Product Portfolio Across Steroidal Build on Fermentation Capabilities and Commercialize Complex Injectables Hormones Expand Biotech Offerings Through Differentiated DDCs Corticosteroid and steroidal hormone Ujjain
Slide 24: Multiple Building Blocks in Place to Fuel Growth Strategies (2/2)
6.2 Multiple Building Blocks in Place to Fuel Growth Strategies (2/2) 4 5 6 Scale Up Diverse Biotech - CDMO Offerings Continue to Invest in New Technologies and Partner With Large Companies for Difficult- Based on Three Interlinked Platforms R&D to-execute Projects Establish a comprehensive, secto
Slide 25: Annexures: Historical Financial Statements
Annexures : Historical Financial Statements 24
Slide 26: Historical Profit & Loss Statement
Historical Profit & Loss Statement Particular (Rs. in Crs) FY26 FY25 FY24 Revenue from Operations 869.1 751.6 716.2 Cost of Goods Sold 315.5 297.4 321.0 Gross Profit 553.7 454.2 395.2 Gross Margins (%) 63.7% 60.4% 55.2% Employees Cost 154.3 122.3 104.1 Other Expenses 161.5 130.0 119.8 Reported EBITD
Slide 27: Historical Balance Sheet
Historical Balance Sheet Particular (Rs. in Crs) FY26 FY25 FY24 Particular (Rs. in Crs) FY26 FY25 FY24 Assets Equity and Liabilities Property, plant and equipment 1084.4 401.5 411.2 Total Equity 1149.6 814.7 714.8 Capital work-in-progress 64.5 568.2 208.3 Borrowings 68.4 253.0 195.2 Investment prope
Slide 28: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (Rs. in Crs) FY26 FY25 FY24 Net Profit Before Tax 153.4 147.0 131.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 85.4 61.9 41.1 Operating profit before working capital changes 238.8 208.9 172.1 Changes in working capital -2.5 -126.
Slide 29: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +10% p.a. +18% p.a. +5% p.a. 869.1 237.9 109.9 751.6 100.1 96.8 716.2 201.8 171.3 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) 60.4% 63.7% 26.9% 27.4% 14.0% 23.
Slide 30: Financial Ratios
Financial Ratios Adjusted ROCE1 OCF To EBITDA2 (x) 30% 1.1 28% 25% 0.8 0.2 FY24 FY25 FY26 FY24 FY25 FY26 Debt to Equity (x) GFTAR3 (x) 0.6 1.5 1.4 1.4 0.3 0.3 FY24 FY25 FY26 FY24 FY25 FY26 (1)Adjusted ROCE after excluding the Capital Employed attributable to Knovea Pharmaceutical Private Limited and
Slide 31: Thank You
Thank You For further Information, please connect : Company: Investor Relations Advisor: Symbiotec Pharmalab Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – U24232MP2002PLC015293 CIN - U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Prabjeet Singh Tank investorrelations@symbiotec.com sagar.shroff@sgapl.
Symbiotec Pharmalab — Q1 FY2027 Earnings Presentation on 6ix